Novartis Home

At Novartis, we are reimagining medicine

Nana, a patient from Ghana who shares her sickle cell story in a village near her home.

World Sickle Cell Day 2019

Discover how Novartis is committed to educating about this disease in sharing patient stories from around the world.

#WorldSickleCellDay

Learn More

Pride @ Novartis 2019

As a company, we stand up for greater inclusion of LGBTI people because when each of us feels included, we all benefit.

#pride

Cell & Gene Therapy at Novartis

Our teams aim to deliver on the promise of cell and gene therapy for patients.

Transparency

Disclosure of transfers of value to healthcare professionals and support to patient groups in accordance with EFPIA Codes and other local laws and regulations.

Payments to Healthcare Professionals
Patient Organization Funding

Novartis Home

At Novartis, we are reimagining medicine

World Sickle Cell Day 2019

Pride @ Novartis 2019

Cell & Gene Therapy at Novartis

Novartis provides update on phase 2b ENCORE-LF trial in NASH cirrhosis

New analysis of Novartis data confirms that Cosentyx® demonstrates durable comprehensive treatment across psoriatic disease

New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy

Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna® use and promising combination data with investigational compound asciminib (ABL001)